Evidence for a two-stage disability progression in multiple sclerosis (Q33944184)

30 July 2017

Evidence for a two-stage disability progression in multiple sclerosis (English)

1 reference

30 July 2017

0 references

0 references

Emmanuelle Leray

1

1 reference

30 July 2017

Jacqueline Yaouanq

2

1 reference

30 July 2017

Emmanuelle Le Page

3

1 reference

30 July 2017

Marc Coustans

4

1 reference

30 July 2017

David Laplaud

5

1 reference

30 July 2017

Joël Oger

6

1 reference

30 July 2017

Gilles Edan

7

1 reference

30 July 2017

language of work or name

English

0 references

publication date

27 April 2010

1 reference

30 July 2017

1 reference

30 July 2017

133

1 reference

30 July 2017

Pt 7

1 reference

30 July 2017

1900-1913

1 reference

Impact of multiple sclerosis relapses on progression diminishes with time

30 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

The relation between inflammation and neurodegeneration in multiple sclerosis brains.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

Natural history of multiple sclerosis: a unifying concept

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

Prognostic factors for multiple sclerosis: the importance of natural history studies.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

Effect of relapses on development of residual deficit in multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

Axonal transection in the lesions of multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

Defining the clinical course of multiple sclerosis: Results of an international survey

5 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

5 July 2018

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

EDMUS, a European database for multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2892936

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

5 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

Making progress on the natural history of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

Age at disability milestones in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

Natural history of multiple sclerosis in a population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

Progression in multiple sclerosis: further evidence of an age dependent process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

Cortical demyelination and diffuse white matter injury in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

Long-term survival of patients with multiple sclerosis in West France.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

Disability progression in multiple sclerosis is slower than previously reported.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FBRAIN%2FAWQ076

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

21 January 2018

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

On the evaluation of disability in multiple sclerosis

1 reference

12 December 2020

Age at onset determines the occurrence of the progressive phase of multiple sclerosis

1 reference

12 December 2020

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

1 reference

12 December 2020

Relapses and progression of disability in multiple sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.1093/BRAIN/AWQ076

1 reference

30 July 2017

1 reference

30 July 2017

1 reference